HEC PRESS Publisher of the
Healthy Eating Club website &
A
sia Pacific Journal of Clinical Nutrition

 


Volume 16 (2007)
1 Issue 1
1 Issue 2
1 Issue 3
1 Issue 4
1 Supplement 1
1 Supplement 2
Volume 15 (2006)
Issue 1
Issue 2
Issue 3
Issue 4
Supplement
Nutrition Society of Australia
Volume 14 (2005)
Issue 1
Supplement on CD
IUNS/APCNS proceedings
Issue 2
Issue 3
Issue 4
Supplement
Nutrition Society of Australia
CURRENT YEAR ISSUES
LOGIN to FULL PAPERS
subscribers only
PAST ISSUES
View full papers (free)
CD-Rom AU$190 vol1-13
NUTRITION SOCIETY OF AUSTRALIA 1976-
View Abstracts
Search our site
 

Asia Pacific J Clin Nutr (1993) 2, 85-89

Motor effects of broad beans (Vicia faba) in Parkinson's disease: single dose studies

PA Kempster1,2 MD, Z Bogetic2 MD, JW Secombei3 BApplSc, HD Martin3 Bsc, NDH Balazs3 Bsc and ML Wahlqvist2 MD

Departments of Neurosciences1, Medicine2 and Biochemistry3, Monash Medical Centre, Melbourne, Australia.

Broad beans (Vicia faba) are a natural source of L-dopa. To investigate a possible role for this substance in the treatment of Parkinsonian motor oscillations, we carried out single dose studies of Vicia faba pod mixture plus carbidopa in six patients. Motor responses of equivalent magnitude to those of conventional L-dopa medication occurred in five cases with mean onset of 39 min and mean duration of 104 min. Vicia faba meals produced comparable L-dopa blood levels to fasting standard tablet doses and recovery studies yielded 0.25% L-dopa per weight of bean pod mixture. Vicia faba contains sufficient L-dopa to be pharmacologically active in patients with Parkinson's disease and can potentially be incorporated into dietary strategies to manage Parkinsonian motor oscillations.


Introduction

Pharmacological treatment of Parkinson's disease with L-dopa is the most practical and physiological way to ameliorate the underlying deficiency of endogenous dopamine release in the striatum. However, the pharmacokinetic properties of orally administered L-dopa lead to fluctuating blood levels, generating 'on-off' fluctuations of motor performance in susceptible patients. Diet, particularly protein intake, contributes to this effect and manipulation of dietary intake has been proposed as a method to reduce fluctuations of L-dopa delivery to the brain.

Food can also be a source of L-dopa. In 1913, Guggenheim first isolated dihydroxyphenylalanine in its levorotatory form after extracting it from Vicia faba beans1. He was also first to demonstrate a pharmacological action of L-dopa when he ingested some of his bean extract and became nauseated. He found the bean pods to be a richer source of L-dopa than the beans.

Vicia faba is a natural food which contains L-dopa in a different physico-chemical form to conventional tablet medication. We have studied the responses to single doses of broad bean mixture to investigate its possible use in the management of Parkinsonian motor oscillations.

Patients and methods

Six patients on chronic conventional L-dopa therapy complicated by moderate to severe motor oscillations were studied. Their mean age was 52 and the mean duration of disease was 16 years. Broad beans (Vicia faba) were purchased in season. Beans and pods were separated by hand while fresh, and the pods were cooked in a microwave oven for ten minutes. The cooked bean pods were then frozen and stored at -70°C until use. Immediately prior to serving, the bean pods were defrosted, fragmented in a food blender and weighed.

Clinical assessments

Each patient was given a dose of bean pod mixture (100200 g) and carbidopa (25-50 mg) after overnight fasting. Normal anti-Parkinsonian medication had been withheld for at least ten hours before. Bean pod mixture and carbidopa doses are shown in Table 1.

Table 1. Summary of motor response characteristics to single Vicia faba mixture doses in each case . For comparison, modified Webster scale scores in relation to conventional L-dopa 100mg/decarboxylase inhibitor doses are shown (see text). N/D = not determined

Case No. Age & Sex Vicia faba (g) Carbidopa (mg) Onset (min) Duration (min) Modified Webster Scale
            Vicia faba mixture Pharmaceutical L-dopa
            Off On Off On
1 51F 100 0 30 30 23 2 23 2
2 41M 150 25 30 75 23 6 23 6
3 48M 100 50 75 60 18 7 18 4
4 54F 150 50 N/D N/D N/D N/D 26 11
5 67M 200 50 20 285 26 1 28 1
6 72F 200 50 45 195 11 9 11 9

Motor response was measured by the following serial objective motor assessments at 15 min intervals:

  1. unilateral hand tapping count over 30 seconds
  2. time taken to rise from a standard armless chair, walk six metres and return to the chair
  3. quantitation of tremor and dyskinesia according to simple five point scales (0 = nil, 1 = mild, 2 = moderate, 3 = severe, 4 = violent/incapacitating) for each body side
  4. scoring on a modified Webster disability scale (scoring for 12 areas of motor function giving a maximum disability score of 36)2.

For the purposes of analysis of the modified Webster scale assessment of motor responses, 'on' phases are defined as at peak post-dose motor improvement and 'off' phases as pre-dose motor score (pre- and post-dose 'off' states did not differ significantly in any case). Amplitude of motor response was calculated by subtracting 'on' from 'off' scores. For comparison, 'on' and 'off' phase modified Webster scoring was carried out in relation to one of each patient's normal L-dopa/decarboxylase inhibitor doses (L-dopa 100 mg/carbidopa 25 mg or L-dopa 100 mg/benserazide 25 mg). In four cases, blood was sampled for plasma L-dopa assay before and at 30 min intervals after the Vicia faba dose until wearing off of motor response. Blood was immediately centrifuged and plasma samples were stored at -70°C.

L-dopa measurements

To plasma samples of 750 m L were added 25m L of 60% perchloric acid plus 50m L of an internal standard compound (dihydroxybenzylamine). Following centrifugation, 500 m L of supernatant was combined with 300 m L of TRIS buffer and 50 mg of Alumina. This was mixed, centrifuged and the supernatant was discarded. The precipitate was washed with distilled water and recentrifuged. To this precipitate was added 500 m L of 0.3N perchloric acid solution to elute L-dopa. Following further centrifugation, 20 m L samples of the supernatant were analysed by HPLC. The apparatus consisted of a BAS 200A liquid chromatograph and electrochemical detector at 0.70 volts oxidation potential. Isocratic elution was carried out at 1.0 ml/min at room temperature on a 10 cm Rainin Microsorb 3 micron ODS reverse phase column. The mobile phase contained citric acid, sodium dihydrogen phosphate and acetonitrile adjusted to pH 2.5. The coefficient of intra-assay variability was 6%.

The ratio of L-dopa concentration at 4 hours post-dose to peak level has been shown to correlate with the time to wearing off of motor response2 and this was used as a measure of the rate of decay of plasma L-dopa concentration.

For measurement of L-dopa recovery from V. faba, 1 g of bean pod mixture was homogenized under ice. This was washed with 20 ml of 0.1M hydrochloric acid containing 0.5% sodium metabisulphite. Following centrifugation, the supernatant was removed and the precipitate rewashed and recentrifuged. The process was repeated four times until no L-dopa could be detected in the supernatant. All supernatants were analysed for L-dopa by HPLC as described above and the total L-dopa content in the original bean pod mix sample was calculated.

Results

In five cases, a clear motor response to the bean mixture occurred. In case 4, severe 'off' phase disability necessitated an injection of apomorphine to allow the meal to be ingested and it was then difficult to differentiate the subsequent motor responses to apomorphine and Vicia faba. This case was excluded from the analysis of the motor assessments but included in the results of the pharmacokinetic studies. Several patients commented on the bland taste of the bean pods but only one described this as unpleasant. Mild nausea occurred 30 min after the meal in one case.

Peak motor improvement in the five patients with unequivocal responses to V. faba was similar to previously observed 'on' phases when taking conventional L-dopa medication. Mean modified Webster scale motor response amplitude was 15 for Vicia faba compared with 16 for conventional treatment (Table 1). The pattern and severity of dyskinesia was also similar for the two sources of L-dopa. Mean onset of response to V. faba was 39 min and mean duration was 104 min. Table 1 shows summarized motor response characteristics in each case and Figure 1 shows serial motor assessment and plasma L-dopa concentration results to compare Vicia faba with a conventional L-dopa medication response in case 5.

Figure 1. Serial motor assessments and plasma L-dopa assays in Case 5 for Vicia faba/carbidopa (squares) and a standard L-dopa 100 mg/carbidopa 25 mg tablet dose (triangles). These studies were performed under similar circumstances on consecutive mornings. Duration of motor response to Vicia faba was 285 mins, compared with 75 mins for conventional L-dopa medication. The prolonged motor response to V. faba corresponded to a much higher plasma L-dopa peak concentration in this case.

L-dopa assays

Results of pharmacokinetic studies are shown in Table 2. Mean time to peak L-dopa concentration was 53 min (30-60). Mean peak L-dopa level was 2.8 m g/ml (0.7-6.3) although the results reflected considerable variability in absorption of L-dopa from the Vicia faba mixture.

2.5 mg of L-dopa was extracted from the 1 g sample bean pod mixture, giving a L-dopa recovery of 0.25% per weight of V. faba pods (L-dopa 250 mg per 100 g of pod mixture).

Table 2. Results of pharmacokinetic studies: peak plasma L-dopa concentration (cmax), time to reach peak level (Tmax) and ratio of plasma L-dopa concentration at peak to four hours post-dose.

Case No. Tmax (min) Cmax (m g/ml) [L-dopah] 4hrs/peak
3 60 1.0 0.29
4 60 0.7 0.20
5 30 6.3 0.21
6 60 1.6 0.25

Discussion

Broad bean pods contain a sufficient quantity of L-dopa to be pharmacologically active in patients with Parkinson's disease. To demonstrate this, we chose to study patients with pronounced motor oscillations. In such cases, fluctuation between distinct 'off' and 'on' motor states occurs. Clear and unequivocal responses to pharmacological agents such as L-dopa or apomorphine which are potent in causing central dopamine receptor stimulation allow the magnitude and time course of such motor responses to be accurately quantified by serial objective motor assessments. In five of the six patients studied, Vicia faba meals produced motor improvement accompanied by dyskinetic involuntary movements in the absence of other dopamine receptor stimulating pharmacological agents. Motor responses following Vicia faba ingestion were generally equivalent to but no better than responses to conventional oral L-dopa doses, suggesting that the motor benefits of Vicia faba can be attributed to their L-dopa content alone, rather than to other pharmacologically active naturally occurring substances. The pharmacokinetics of L-dopa from Vicia faba were comparable to those of fasting oral L-dopa/ decarboxylase inhibitor tablet doses in terms of peak levels and decay of L-dopa concentration2. The pod mixture does not have the characteristics of a slow release L-dopa preparation3. Our finding of L-dopa recovery of 0.25% per weight of Vicia faba pods was identical to that of Guggenheim, who used stoichiometric methods to measure the L-dopa content of a sample of fresh bean pods1. Our pharmacokinetic data is consistent with L-dopa bioavailability from Vicia faba Of that order of magnitude.

Most of the L-dopa contained in Vicia faba exists in a free form in the bean pods although small quantities of a dopa glucoside can be detected in both legumes and pods4. L-dopa also occurs naturally in significant quantities in several other leguminous species. It is present in the Georgia velvet bean (Stizolobium deeringianum)5 and the legumes and seeds of the Indian medicinal plant Mucuna pruriens6. The L-dopa yield per weight of the latter plant is considerably greater than lo from Vicia faba.

Natural sources of L-dopa cannot compete with tablet formulations for convenience and predictable bio-availability. However, Vicia faba does have some potential advantages in reducing the interaction between oral L-dopa medication and diet. High protein meals will antagonize transmembrane passage of L-dopa across the gut and the blood-brain barrier7 and dietary protein restriction has been shown to improve responsiveness to L-dopa in some patients8.

Vicia faba is a relatively rich protein source (if both legumes and pods are ingested)9 which has demonstrably positive effects on both plasma L-dopa concentration and motor function. It is inexpensive, both as a nutritional substance and as a pharmacological treatment. Rather than simply restricting oral protein intake, a diet which substitutes Vicia faba for other protein-rich foods, in conjunction with conventional L-dopa/decarboxylase inhibitor medicaton, may have a stabilizing effect on motor fluctuations and reduce food induced 'off' phases.

Anecdotal reports that patients may gain benefit from a broad bean rich diet10 and findings on L-dopa absorption and motor response characteristics following single Vicia faba doses11 suggest that this strategy is worthy of further study as an adjunct to the management of Parkinsonian motor fluctuations.

Acknowledgements - We are grateful for the assistance of Mr Len Edwards who provided practical advice on the preparation and effects of broad bean mixture. Mr Sam Lai assisted with the graphical production of the Figure.

References

  1. Guggenheim M. Dioxyphenylalanine, a new amino acid from Vicia faba. Z Physiol Chem 1913;88:276.
  2. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-723.
  3. Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DS. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39(suppl 2):25-38.
  4. Andrews RS, Pridham JB. Structure of a dopa glucoside from Vicia faba. Nature 1965;205:1213-1214.
  5. Miller ER. Dihydroxyphenylalanine, a constituent of the velvet bean. J Biol Chem 1920;44:481-486.
  6. Damodaran M, Ramaswamy R. Isolation of L-3,4dihydroxyphenylalanine from the seeds of Mucuna pruriens. Biochem J 1937;31:2149-2152.
  7. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL, 'On-off' phenomenon in Parkinson's disease: relation to L-dopa absorption and transport. New Eng J Med 1984;310:483-488.
  8. Pincus JH, Barry KM. Protein redistribution diet restores motor function in patients with dopa-resistant 'off' periods. Neurology 1988;38:481-483.
  9. Duke JA. Handbook of legumes of world economic importance. Plenum Press: New York 1981:275-279.
  10. Spengos M, Vassilopoulos D. Improvement of Parkinson's disease after Vicia faba consumption. Book of abstracts, 9th International Symposium on Parkinson's disease 1988:46.
  11. Rabey JM, Vered Y, Shabtai H, Graff E, Korczyn AD. Improvement of Parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry 1992;55:725-727.


Copyright © 1993 [Asia Pacific Journal of Clinical Nutrition]. All rights reserved.
Please note: this article has been scanned and reformatted.

to the top